Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRaG Therapy for Salvage Local Recurrence After Pancreatic Cancer Surgery
ChiCTR2600126225Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of granulocyte macrophage-colony stimulating factor in pancreatic cancer (PC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-Free Survival (PFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
granulocyte macrophage-colony stimulating factor
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2600126225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126225.